Blogs
May 6, 2026
Warren Buffett's 1996 letter framework classifies businesses into Inevitables, Highly Probables and Hopefuls. Most Indian retail portfolios mistake tier three for tier one. Titan Biotech FY25's audited numbers read as a Highly Probable profile.
May 5, 2026
Ellen Langer's 1975 illusion-of-control experiments explain why 91.1% of Indian F&O traders lose money — and the 8-point counter-measure checklist serious long-term investors must install. Titan Biotech FY25's ₹3 Cr borrowings, 103% CFO/Operating Profit, and 36.4% independent-board ratio illustrate the corporate analogue of the anti-bias discipline (educational case study, not a valuation call).
May 5, 2026
A long-form educational deep-dive on Other Income as a percentage of Profit Before Tax — the 30-second forensic earnings-quality filter that separates real Indian operating businesses from non-operating bookkeepers. Illustrated using Titan Biotech FY25 audited disclosures (operating-led ~₹214 Cr revenue, ~18-22% EBITDA margin, CFO/Operating Profit at ~103%, total borrowings ₹3 Cr) as a positive educational example. Educational content only — not a buy/sell recommendation.
May 5, 2026
Economic Goodwill: Warren Buffett’s 1983 Berkshire Letter Appendix on the Real Source of Compounding
Buffett's 1983 appendix split goodwill into two: the accountant's residual on the balance sheet, and the inflation-resistant economic goodwill that compounds wealth. Titan Biotech FY25's high returns on a modest tangible base read like the second.
